Literature DB >> 16675358

Mycoplasma in severe asthma.

Monica Kraft1, Qutayba Hamid.   

Abstract

Entities:  

Mesh：

Year:  2006        PMID： 16675358     DOI： 10.1016/j.jaci.2006.03.001

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  12 in total

1.  Mast cell TNF receptors regulate responses to Mycoplasma pneumoniae in surfactant protein A (SP-A)-/- mice.

Authors:  Bethany J Hsia; Julie G Ledford; Erin N Potts-Kant; Vinayak S Nikam; Njira L Lugogo; W Michael Foster; Monica Kraft; Soman N Abraham; Jo Rae Wright
Journal:  J Allergy Clin Immunol       Date:  2012-04-12       Impact factor: 10.793

2.  Interleukin-17A Exacerbates Disease Severity in BALB/c Mice Susceptible to Lung Infection with Mycoplasma pulmonis.

Authors:  Maximillion T Mize; Xiangle L Sun; Jerry W Simecka
Journal:  Infect Immun       Date:  2018-08-22       Impact factor: 3.441

3.  Genetic variation in SP-A2 leads to differential binding to Mycoplasma pneumoniae membranes and regulation of host responses.

Authors:  Julie G Ledford; Dennis R Voelker; Kenneth J Addison; Ying Wang; Vinayak S Nikam; Simone Degan; Pitachaimani Kandasamy; Sasipa Tanyaratsrisakul; Bernard M Fischer; Monica Kraft; John W Hollingsworth
Journal:  J Immunol       Date:  2015-05-08       Impact factor: 5.422

4.  Interleukin 1 Receptor-Like 1 (IL1RL1) Promotes Airway Bacterial and Viral Infection and Inflammation.

Authors:  Niccolette Schaunaman; Amelia Sanchez; Kris Genelyn Dimasuay; Nicole Pavelka; Mari Numata; Rafeul Alam; Richard J Martin; Hong Wei Chu
Journal:  Infect Immun       Date:  2019-06-20       Impact factor: 3.441

5.  Toll-like receptor 2 (TLR2) plays a major role in innate resistance in the lung against murine Mycoplasma.

Authors:  Wees Love; Nicole Dobbs; Leslie Tabor; Jerry W Simecka
Journal:  PLoS One       Date:  2010-05-20       Impact factor: 3.240

6.  Intranasal interleukin-12 therapy inhibits Mycoplasma pneumoniae clearance and sustains airway obstruction in murine pneumonia.

Authors:  C M Salvatore; M Fonseca-Aten; K Katz-Gaynor; A M Gomez; R D Hardy
Journal:  Infect Immun       Date:  2007-11-26       Impact factor: 3.441

7.  Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.

Authors:  C M Salvatore; C Techasaensiri; C Tagliabue; K Katz; N Leos; A M Gomez; G H McCracken; R D Hardy
Journal:  Antimicrob Agents Chemother       Date:  2009-01-12       Impact factor: 5.191

8.  A 20-Mer Peptide Derived from the Lectin Domain of SP-A2 Decreases Tumor Necrosis Factor Alpha Production during Mycoplasma pneumoniae Infection.

Authors:  Usir S Younis; Hong Wei Chu; Monica Kraft; Julie G Ledford
Journal:  Infect Immun       Date:  2020-08-19       Impact factor: 3.441

9.  Inhibition of message for FcepsilonRI alpha chain blocks mast cell IL-4 production induced by co-culture with Mycoplasma pneumoniae.

Authors:  Danlin Luo; Yuling Dai; Lynn B Duffy; T Prescott Atkinson
Journal:  Microb Pathog       Date:  2007-10-24       Impact factor: 3.738

10.  Surfactant protein-A suppresses eosinophil-mediated killing of Mycoplasma pneumoniae in allergic lungs.

Authors:  Julie G Ledford; Sambuddho Mukherjee; Michele M Kislan; Julia L Nugent; John W Hollingsworth; Jo Rae Wright
Journal:  PLoS One       Date:  2012-02-23       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.